Skip to main content
Erschienen in: Die Innere Medizin 11/2022

23.09.2022 | Zytostatische Therapie | Schwerpunkt: Klonale Hämatopoese

Klonale Hämatopoese und solide Neoplasien

verfasst von: Dr. med. Christopher Maximilian Arends, Prof. Dr. med. Frederik Damm

Erschienen in: Die Innere Medizin | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Klonale Hämatopoese (CH) ist ein im Alter häufig auftretender prämaligner Zustand des hämatopoetischen Systems, der mit einem erhöhten kardiovaskulären Risiko und einer erhöhten Gesamtsterblichkeit einhergeht.

Fragestellung

Prävalenz und klinische Implikationen der CH bei PatientInnen mit soliden Neoplasien.

Material und Methoden

Sichtung, Zusammenfassung und Diskussion der Literatur.

Ergebnisse

CH tritt bei etwa 20–30 % der PatientInnen mit soliden Neoplasien auf. CH-Mutationen können bei der molekulargenetischen Analyse von Tumormaterial oder zellfreier DNA aus Plasma als Tumormutationen missinterpretiert werden. CH und insbesondere Mutationen in Genen der DNA-Reparatur-Maschinerie sind unter Chemo‑, Strahlen- und Poly-(Adenosindiphosphat-Ribose)-Polymerase-Inhibitor-Therapie mit einem erhöhten Risiko therapieassoziierter myeloischer Neoplasien (t-MN) assoziiert.

Schlussfolgerung

CH ist ein häufiges Phänomen bei PatientInnen mit soliden Neoplasien und hat aufgrund des t‑MN-Risikos eine hohe klinische Relevanz. Weitere Studien sind notwendig, um die Rolle der CH in diesem Patientenkollektiv besser zu verstehen und um evidenzbasierte Handlungsempfehlungen ableiten zu können.
Literatur
1.
Zurück zum Zitat Acuna-Hidalgo R, Sengul H, Steehouwer M et al (2017) Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet 101:50–64 PubMedPubMedCentralCrossRef Acuna-Hidalgo R, Sengul H, Steehouwer M et al (2017) Ultra-sensitive sequencing identifies high prevalence of clonal hematopoiesis-associated mutations throughout adult life. Am J Hum Genet 101:50–64 PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Arends CM, Dimitriou S, Stahler A et al (2022) Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE‑3 trial. Blood 139:1593–1597 PubMedCrossRef Arends CM, Dimitriou S, Stahler A et al (2022) Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE‑3 trial. Blood 139:1593–1597 PubMedCrossRef
4.
Zurück zum Zitat Avagyan S, Henninger JE, Mannherz WP et al (2021) Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374:768–772 PubMedCrossRef Avagyan S, Henninger JE, Mannherz WP et al (2021) Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374:768–772 PubMedCrossRef
5.
6.
Zurück zum Zitat Boettcher S, Miller PG, Sharma R et al (2019) A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365:599–604 PubMedPubMedCentralCrossRef Boettcher S, Miller PG, Sharma R et al (2019) A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365:599–604 PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Bolton KL, Gillis NK, Coombs CC et al (2019) Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol 37:7–11 PubMedCrossRef Bolton KL, Gillis NK, Coombs CC et al (2019) Managing clonal hematopoiesis in patients with solid tumors. J Clin Oncol 37:7–11 PubMedCrossRef
8.
9.
Zurück zum Zitat Bolton KL, Zehir A, Ptashkin RN et al (2020) The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic. Hematol Oncol Clin North Am 34:357–367 PubMedCrossRef Bolton KL, Zehir A, Ptashkin RN et al (2020) The clinical management of clonal hematopoiesis: creation of a clonal hematopoiesis clinic. Hematol Oncol Clin North Am 34:357–367 PubMedCrossRef
10.
Zurück zum Zitat Bowen D, Groves MJ, Burnett AK et al (2009) TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 23:203–206 PubMedCrossRef Bowen D, Groves MJ, Burnett AK et al (2009) TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 23:203–206 PubMedCrossRef
11.
12.
Zurück zum Zitat Christen F, Hablesreiter R, Hoyer K et al (2022) Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia 36:1102–1110 PubMedCrossRef Christen F, Hablesreiter R, Hoyer K et al (2022) Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia 36:1102–1110 PubMedCrossRef
13.
Zurück zum Zitat Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405–1413 PubMedCrossRef Christiansen DH, Andersen MK, Pedersen-Bjergaard J (2001) Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 19:1405–1413 PubMedCrossRef
14.
Zurück zum Zitat Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949–1961 PubMedPubMedCentralCrossRef Coleman RL, Oza AM, Lorusso D et al (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1949–1961 PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Coombs CC, Gillis NK, Tan X et al (2018) Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res 24:5918–5924 PubMedPubMedCentralCrossRef Coombs CC, Gillis NK, Tan X et al (2018) Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clin Cancer Res 24:5918–5924 PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21:374–382.e4 PubMedPubMedCentralCrossRef Coombs CC, Zehir A, Devlin SM et al (2017) Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21:374–382.e4 PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Damm F, Mylonas E, Cosson A et al (2014) Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4:1088–1101 PubMedCrossRef Damm F, Mylonas E, Cosson A et al (2014) Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4:1088–1101 PubMedCrossRef
18.
Zurück zum Zitat Fisher AE, Hochegger H, Takeda S et al (2007) Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol 27:5597–5605 PubMedPubMedCentralCrossRef Fisher AE, Hochegger H, Takeda S et al (2007) Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol 27:5597–5605 PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Fraietta JA, Nobles CL, Sammons MA et al (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307–312 PubMedPubMedCentralCrossRef Fraietta JA, Nobles CL, Sammons MA et al (2018) Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558:307–312 PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Fuster JJ, Maclauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847 PubMedPubMedCentralCrossRef Fuster JJ, Maclauchlan S, Zuriaga MA et al (2017) Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355:842–847 PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Genovese G, Kahler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487 PubMedPubMedCentralCrossRef Genovese G, Kahler AK, Handsaker RE et al (2014) Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371:2477–2487 PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Ghoneim HE, Fan Y, Moustaki A et al (2017) De novo epigenetic programs inhibit PD‑1 blockade-mediated T cell rejuvenation. Cell 170:142–157.e19 PubMedPubMedCentralCrossRef Ghoneim HE, Fan Y, Moustaki A et al (2017) De novo epigenetic programs inhibit PD‑1 blockade-mediated T cell rejuvenation. Cell 170:142–157.e19 PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Gillis NK, Ball M, Zhang Q et al (2017) Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol 18:112–121 PubMedCrossRef Gillis NK, Ball M, Zhang Q et al (2017) Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol 18:112–121 PubMedCrossRef
24.
Zurück zum Zitat Goodall J, Mateo J, Yuan W et al (2017) Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 7:1006–1017 PubMedPubMedCentralCrossRef Goodall J, Mateo J, Yuan W et al (2017) Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 7:1006–1017 PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Hsu JI, Dayaram T, Tovy A et al (2018) PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23:700–713.e6 PubMedPubMedCentralCrossRef Hsu JI, Dayaram T, Tovy A et al (2018) PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy. Cell Stem Cell 23:700–713.e6 PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Hu Y, Ulrich BC, Supplee J et al (2018) False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 24:4437–4443 PubMedCrossRef Hu Y, Ulrich BC, Supplee J et al (2018) False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res 24:4437–4443 PubMedCrossRef
27.
Zurück zum Zitat Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498 PubMedPubMedCentralCrossRef Jaiswal S, Fontanillas P, Flannick J et al (2014) Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371:2488–2498 PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377:111–121 PubMedPubMedCentralCrossRef Jaiswal S, Natarajan P, Silver AJ et al (2017) Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med 377:111–121 PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Jensen K, Konnick EQ, Schweizer MT et al (2021) Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol 7:107–110 PubMedCrossRef Jensen K, Konnick EQ, Schweizer MT et al (2021) Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol 7:107–110 PubMedCrossRef
30.
Zurück zum Zitat Kahn JD, Miller PG, Silver AJ et al (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095–1105 PubMedPubMedCentralCrossRef Kahn JD, Miller PG, Silver AJ et al (2018) PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132:1095–1105 PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250 PubMedCrossRef Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:244–250 PubMedCrossRef
32.
Zurück zum Zitat Kwan TT, Oza AM, Tinker AV et al (2021) Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol 7:1772–1781 PubMedCrossRef Kwan TT, Oza AM, Tinker AV et al (2021) Preexisting TP53-variant clonal hematopoiesis and risk of secondary myeloid neoplasms in patients with high-grade ovarian cancer treated with rucaparib. JAMA Oncol 7:1772–1781 PubMedCrossRef
33.
Zurück zum Zitat Lee M, Li J, Li J et al (2021) Tet2 inactivation enhances the antitumor activity of tumor-infiltrating lymphocytes. Cancer Res 81:1965–1976 PubMedPubMedCentralCrossRef Lee M, Li J, Li J et al (2021) Tet2 inactivation enhances the antitumor activity of tumor-infiltrating lymphocytes. Cancer Res 81:1965–1976 PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Liu X, Sato N, Shimosato Y et al (2022) CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Sci 113:1182–1194 PubMedPubMedCentralCrossRef Liu X, Sato N, Shimosato Y et al (2022) CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression. Cancer Sci 113:1182–1194 PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Mayrhofer M, De Laere B, Whitington T et al (2018) Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med 10:85 PubMedPubMedCentralCrossRef Mayrhofer M, De Laere B, Whitington T et al (2018) Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Med 10:85 PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Morice PM, Leary A, Dolladille C et al (2021) Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 8:e122–e134 PubMedCrossRef Morice PM, Leary A, Dolladille C et al (2021) Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 8:e122–e134 PubMedCrossRef
39.
Zurück zum Zitat Moss J, Magenheim J, Neiman D et al (2018) Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 9:5068 PubMedPubMedCentralCrossRef Moss J, Magenheim J, Neiman D et al (2018) Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat Commun 9:5068 PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Pan W, Zhu S, Qu K et al (2017) The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity 47:284–297.e5 PubMedPubMedCentralCrossRef Pan W, Zhu S, Qu K et al (2017) The DNA methylcytosine dioxygenase Tet2 sustains immunosuppressive function of tumor-infiltrating myeloid cells to promote melanoma progression. Immunity 47:284–297.e5 PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Razavi P, Li BT, Brown DN et al (2019) High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med 25:1928–1937 PubMedPubMedCentralCrossRef Razavi P, Li BT, Brown DN et al (2019) High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nat Med 25:1928–1937 PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Sano S, Oshima K, Wang Y et al (2018) Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 Inflammasome. J Am Coll Cardiol 71:875–886 PubMedPubMedCentralCrossRef Sano S, Oshima K, Wang Y et al (2018) Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 Inflammasome. J Am Coll Cardiol 71:875–886 PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Singh A, Mencia-Trinchant N, Griffiths EA et al (2022) Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol 6:e2100309 PubMedCrossRef Singh A, Mencia-Trinchant N, Griffiths EA et al (2022) Mutant PPM1D- and TP53-driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy. JCO Precis Oncol 6:e2100309 PubMedCrossRef
44.
Zurück zum Zitat Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16 PubMedPubMedCentralCrossRef Steensma DP, Bejar R, Jaiswal S et al (2015) Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126:9–16 PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Swisher EM, Lin KK, Oza AM et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75–87 PubMedCrossRef Swisher EM, Lin KK, Oza AM et al (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 18:75–87 PubMedCrossRef
46.
Zurück zum Zitat Takahashi K, Wang F, Kantarjian H et al (2017) Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18:100–111 PubMedCrossRef Takahashi K, Wang F, Kantarjian H et al (2017) Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 18:100–111 PubMedCrossRef
47.
Zurück zum Zitat Watson CJ, Papula AL, Poon GYP et al (2020) The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367:1449–1454 PubMedCrossRef Watson CJ, Papula AL, Poon GYP et al (2020) The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367:1449–1454 PubMedCrossRef
48.
Zurück zum Zitat Weber-Lassalle K, Ernst C, Reuss A et al (2022) Clonal hematopoiesis-associated gene mutations in a clinical cohort of 448 patients with ovarian cancer. J Natl Cancer Inst 114:565–570 PubMedCrossRef Weber-Lassalle K, Ernst C, Reuss A et al (2022) Clonal hematopoiesis-associated gene mutations in a clinical cohort of 448 patients with ovarian cancer. J Natl Cancer Inst 114:565–570 PubMedCrossRef
49.
Zurück zum Zitat Wong TN, Ramsingh G, Young AL et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552–555 PubMedCrossRef Wong TN, Ramsingh G, Young AL et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552–555 PubMedCrossRef
50.
Zurück zum Zitat Xie M, Lu C, Wang J et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478 PubMedPubMedCentralCrossRef Xie M, Lu C, Wang J et al (2014) Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med 20:1472–1478 PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Young AL, Challen GA, Birmann BM et al (2016) Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 7:12484 PubMedPubMedCentralCrossRef Young AL, Challen GA, Birmann BM et al (2016) Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 7:12484 PubMedPubMedCentralCrossRef
Metadaten
Titel
Klonale Hämatopoese und solide Neoplasien
verfasst von
Dr. med. Christopher Maximilian Arends
Prof. Dr. med. Frederik Damm
Publikationsdatum
23.09.2022
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 11/2022
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-022-01404-x

Weitere Artikel der Ausgabe 11/2022

Die Innere Medizin 11/2022 Zur Ausgabe

Mitteilungen des BDI

Mitteilungen des BDI

Mitteilungen der DGIM

Mitteilungen der DGIM

Passend zum Thema

DKK 2024
21. - 24. Februar 2024 | Berlin

Kongressdossier zum Deutschen Krebskongress 2024

Auf dieser Seite werden wir Sie mit tagesaktuellen Berichten vom Deutschen Krebskongress auf dem Laufenden halten. Vor dem Start des Kongresses finden Sie hier zudem Ausblicke auf spannende Themen. Expertinnen und Experten erzählen, auf welche DKK-Sessions sie sich besonders freuen.

In Kooperation mit:
Deutsche Krebsgesellschaft e. V. und Stiftung Deutsche Krebshilfe